ICMR Pulls Ivermectin from COVID-19 Treatments While Promoting Remdesivir & Roche’s Tocilizumab

ICMR Pulls Ivermectin from COVID-19 Treatments While Promoting Remdesivir & Roche’s Tocilizumab

Multiple press in India report that the Indian Council of Medical Research (ICMR), the apex research institute for the world’s second-most populous nation, and its COVID-19 National Task Force moved to finally remove ivermectin as well as hydroxychloroquine from the revised “clinical guidance for management of adult COVID-19 patients.” The top national research institute declares that the drugs can be used during any trial settings but will no longer recommend the use of the drug as an antiviral-like medication. The drug has been heavily used in India during the pandemic, especially in select states such as Uttar Pradesh where it was part of an aggressive public health strategy involving outreach to the cities and provinces.

ICMR declared there is no mortality benefit associated with the drugs while the existing studies in the nation don’t demonstrate clear enough efficacy data to warrant national evidence status. For example, ICMR cites an All India Institute of Medical Science (AIIMS) study involving 157 patients admitted to the hospital with mild to moderate COVID-19 between July and September 2020.

Meanwhile, the Hindu Business Line published a report declaring...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee